Aerovate Therapeutics (AVTE) Competitors $7.95 -0.08 (-1.00%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. TRVI, URGN, PHAT, IOVA, IMNM, QURE, AVXL, AKBA, AMLX, and NAGEShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), Iovance Biotherapeutics (IOVA), Immunome (IMNM), uniQure (QURE), Anavex Life Sciences (AVXL), Akebia Therapeutics (AKBA), Amylyx Pharmaceuticals (AMLX), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Trevi Therapeutics Urogen Pharma Phathom Pharmaceuticals Iovance Biotherapeutics Immunome uniQure Anavex Life Sciences Akebia Therapeutics Amylyx Pharmaceuticals Niagen Bioscience Aerovate Therapeutics (NASDAQ:AVTE) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do institutionals and insiders believe in AVTE or TRVI? 95.8% of Trevi Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer AVTE or TRVI? Trevi Therapeutics has a consensus target price of $20.11, indicating a potential upside of 178.93%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Is AVTE or TRVI more profitable? Trevi Therapeutics' return on equity of -41.44% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Trevi Therapeutics N/A -41.44%-38.21% Which has more risk and volatility, AVTE or TRVI? Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Does the media prefer AVTE or TRVI? In the previous week, Trevi Therapeutics had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Trevi Therapeutics and 0 mentions for Aerovate Therapeutics. Trevi Therapeutics' average media sentiment score of 0.64 beat Aerovate Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Trevi Therapeutics Positive Which has better valuation & earnings, AVTE or TRVI? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.68Trevi TherapeuticsN/AN/A-$47.91M-$0.42-17.17 SummaryTrevi Therapeutics beats Aerovate Therapeutics on 11 of the 14 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.43M$848.50M$5.78B$9.79BDividend YieldN/A4.84%3.95%4.02%P/E Ratio-2.661.1331.2626.59Price / SalesN/A26.55453.73167.91Price / CashN/A19.5637.7359.36Price / Book2.016.7310.046.68Net Income-$75.52M-$4.20M$3.27B$265.59M7 Day Performance7.72%16.11%1.34%0.66%1 Month Performance2.58%17.10%6.13%2.64%1 Year Performance-87.72%34.92%41.90%22.36% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$7.95-1.0%N/A-87.8%$230.43MN/A-2.6620High Trading VolumeTRVITrevi Therapeutics2.8628 of 5 stars$7.39+1.4%$20.11+172.3%+144.4%$899.32MN/A-17.5820News CoverageGap UpURGNUrogen Pharma4.5868 of 5 stars$19.30+4.3%$32.00+65.8%+36.6%$892.82M$90.40M-5.81200Positive NewsPHATPhathom Pharmaceuticals2.6243 of 5 stars$12.58+8.8%$17.50+39.1%-23.8%$892.69M$114.04M-2.66110IOVAIovance Biotherapeutics4.6039 of 5 stars$2.45-3.4%$11.90+386.7%-80.3%$884.72M$164.07M-1.99500IMNMImmunome1.615 of 5 stars$10.09+1.7%$22.50+123.1%-36.3%$877.94M$12.59M-3.2740Analyst ForecastQUREuniQure2.4132 of 5 stars$15.67+0.8%$37.45+139.0%+168.1%$857.02M$27.12M-3.98500AVXLAnavex Life Sciences3.7634 of 5 stars$9.56+1.7%$44.00+360.3%+56.8%$821.11MN/A-16.7740Analyst ForecastAKBAAkebia Therapeutics3.8093 of 5 stars$3.07+1.2%$6.75+120.2%+104.6%$812.65M$160.18M-18.03430AMLXAmylyx Pharmaceuticals3.3865 of 5 stars$8.98+5.6%$11.75+30.9%+350.7%$800.30M$87.37M-3.59200News CoverageAnalyst ForecastNAGENiagen Bioscience1.1925 of 5 stars$10.03flat$13.42+33.8%N/A$799.89M$99.60M47.76120 Related Companies and Tools Related Companies Trevi Therapeutics Competitors Urogen Pharma Competitors Phathom Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Immunome Competitors uniQure Competitors Anavex Life Sciences Competitors Akebia Therapeutics Competitors Amylyx Pharmaceuticals Competitors Niagen Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access